Unsafe Chinese Drugs Result in Thousands of Deaf Children Every Year

Leo Timm
By Leo Timm
November 28, 2016News
share
Unsafe Chinese Drugs Result in Thousands of Deaf Children Every Year

A PSA commercial by China’s state-run television reveals the startling reality of Chinese pharmaceuticals

In a public announcement, China’s state-run television CCTV has a simple message to parents: children are not miniatures of adults when it comes to taking medication. The video, however, fails to point out the root cause behind the problem.

The three-minute video consists of five-year-old deaf girl named Fu Xinuo making hand signs into the camera, with subtitles in Chinese. At the beginning of the video, the happy-looking Fu says that her parents told her that she could start calling them “mom” and “dad” when she was one year old, and she would “jump up and down” when hearing music. Then, Fu begins to tear up slowly as she gestures how her hearing slowly deteriorated because of improper medication for a fever three years ago.

“Mom, I am afraid, I am afraid to play with other children,” read the subtitles.

“Sometimes I get angry and throw stuff on the floor,” the subtitles continue as Xi cries. “It’s not that I don’t behave. I just that I want to speak to you, mom, but I am too anxious to say any words.”

Then a startling fact appears: “Because of improper medication, there are annually about 30,000 students who have gone deaf, in addition to suffering kidney, liver, and nerve damage.”

“Children are not miniature version of you. Children need medication for children,” the video states.

Read the full article on Epoch Times. 

Featured image: Fu Xinuo, a Chinese child made deaf due to unsafe medication, gives a warning in September about unsafe medication in China that is harming tens of thousands of children annually. Credit: CCTV.com

ntd newsletter icon
Sign up for NTD Daily
What you need to know, summarized in one email.
Stay informed with accurate news you can trust.
By registering for the newsletter, you agree to the Privacy Policy.
Comments